metastatic-cancer-drugs-market-size.jpg
Metastatic Cancer Drug Market Thrives with Collaborative Innovations: Pfizer, Sanofi, and Merck Leading the Charge
September 15, 2023 10:18 ET | Research and Markets
Dublin, Sept. 15, 2023 (GLOBE NEWSWIRE) -- The "Global Metastatic Cancer Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Indication, By Therapy (Targeted...
Global Precision Medicine Market
Global Precision Medicine Market Soars to $100.5 Billion by 2028, Fueled by Personalized Healthcare Demand and Technological Advancements
September 04, 2023 10:39 ET | Research and Markets
Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Precision Medicine: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global precision medicine market, valued at...
Global Precision Oncology Market
Global Precision Oncology Research Report 2023: A Projected $225+ Billion Industry by 2031 - Explore Precision Oncology's Rise
September 04, 2023 05:28 ET | Research and Markets
Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Global Precision Oncology Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global precision...
ptx-logo .png
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
August 29, 2023 08:30 ET | Prelude Therapeutics, Inc.
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will...
ptx-logo .png
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 03, 2023 08:00 ET | Prelude Therapeutics, Inc.
Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into 2026, enabling advancement of Prelude’s pipeline through...
ITM eröffnet neue Prdouktionsstätte, vlnr: ITM COO, Aufsichtsratsvorsitzender, Staatsminister, ITM CEO, Bürgermeister Neufahrn
ITM eröffnet weltweit größte Anlage zur Produktion von Lutetium-177 für zielgerichtete Radionuklidtherapien gegen Krebs
June 13, 2023 02:00 ET | ITM Isotope Technologies Munich SE
Neue Herstellungsanlage in Neufahrn bei München verzehnfacht ITMs Produktionskapazitäten Feierliche Eröffnung durch Staatsminister Dr. Florian Herrmann, Leiter der Bayerischen Staatskanzlei ...
ITM opens new production facility:ITM COO, ITM Chairman of the Board, Minister of State, ITM CEO, Mayor Neufahrn
ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
June 13, 2023 02:00 ET | ITM Isotope Technologies Munich SE
New manufacturing plant in Neufahrn near Munich increases ITM's production capacity tenfoldCeremonial opening by Minister of State, Dr. Florian Herrmann, Head of the Bavarian State Chancellery ...
ITM_Logo_Claim_RGB_high-res.png
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
June 05, 2023 05:00 ET | ITM Isotope Technologies Munich SE
 One of the largest private investment rounds in European biotech to-dateNet proceeds will enhance ITM’s radiopharmaceutical pipeline, bolster commercial infrastructure, expand leading...
ptx-logo .png
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
May 08, 2023 08:30 ET | Prelude Therapeutics, Inc.
Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE...
ptx-logo .png
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
April 27, 2023 08:30 ET | Prelude Therapeutics, Inc.
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will...